Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography

Evaluate the diagnostic accuracy of the Planmed Sophie Nuance Full Field Digital Mammography (FFDM) X-ray System compared to screen-film mammography (SFM) in the detection of breast cancer.

Study Overview

• Status: Withdrawn
• Conditions: Breast Cancer
• Intervention / Treatment: Device: Full Field Digital Mammogram (Planmed Sophie Nuance)

Detailed Description

Objectives: 1) To establish the non-inferiority of the diagnostic accuracy of the Planmed Sophie Nuance Full Field Digital Mammography (FFDM) X-ray System compared to screen-film mammography (SFM) in the detection of breast cancer; and 2) To demonstrate in a comparative side-by-side feature analysis that interpretations based on the Planmed Sophie Nuance FFDM X-ray System are diagnostically non-inferior to SFM in the detection of breast cancer.

• Study Type: Interventional
• Enrollment (Anticipated): 250
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Tennessee
    • Memphis, Tennessee, United States, 38119
      • Mroz-Baier Breast Care Clinic
  • Texas
    • Houston, Texas, United States, 77034
      • The Rose

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Subject is 40 years of age or older
2. Subject is presenting for routine breasts cancer screening (Cohort I) OR Subject has one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography (Cohort II)
3. Subject's schedule permits the SFM and the FFDM to be performed no more than 30 days apart and with no intervention between the exams
4. Subject will provide prospective, written informed consent
5. Subject is considered capable of complying with study procedures including a willingness to return for a one-year follow-up exam -

Exclusion Criteria:

1. Subject is pregnant or possibly pregnant or planning pregnancy within the next 15 months

2. Subject has undergone a breast augmentation or breast implant? Has subject had any of the following breast procedures?

   Fine needle or cyst aspiration NOT Eligible if within past year Biopsy Not Eligible if within past year Lumpectomy (for breast cancer) Mastectomy (for breast cancer) Radiation therapy Breast reconstruction Breast reduction Not Eligible if within past year

3. Subject has had an invasive breast procedure or operation within the past year
4. Subject has significant existing breast trauma
5. Subject has a history of breast cancer treated with operation or radiation
6. Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: mammography; Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography	Device: Full Field Digital Mammogram (Planmed Sophie Nuance); Full Field Digital Mammogram; Other Names: mammography; digital mammography

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Area under ROC curve based on subjects' maximum POM scores; sensitivity based on subjects' maximum BI-RADS scores with 4 or higher as positive for cancer; and specificity based on subjects maximum BI-RADS scores with 4 or higher as positive for cancer	Approximately one year after completion of study.

Secondary Outcome Measures

Outcome Measure	Time Frame
area under the ROC curve based on the maximum POM score per subject-breast	Approximately one year after completion of study.
area under the ROC curve based on the POM scores from the ten regions of a subject's breasts;	Approximately one year after completion of study.
sensitivity based on subjects' maximum BI-RADS scores using a cut-point of 3 or higher as positive for cancer;	Approximately one year after completion of study.
specificity based on subjects' maximum BI-RADS scores using a cut-point of 3 or higher as positive for cancer;	Approximately one year after completion of study.
Sensitivity and specificity based on the maximum BI-RADS scores per subject-breast using 4 or higher for positive; and sensitivity and specificity based on the maximum BI-RADS scores per subject-breast using 3 or higher for positive.	Approximately one year after completion of study.
Feature Analysis Study; side by side assessment of SFM and FFDM images and comparison of quality features: lesion conspicuity, tissue visibility at chest wall, tissue visibility at skin line, axillary details (MLO), overall contrast, overall sharpness	Approximately one year after completion of study.
Adverse event assessment	Approximately 24 hours after completion of FFDM

Collaborators and Investigators

• Sponsor: Planmed Oy
• Investigators: Study Director: Sami Tohka, PhD, Planmed Oy

Study record dates

Study Major Dates

• Study Start: April 1, 2008
• Primary Completion (Anticipated): March 1, 2011
• Study Completion (Anticipated): March 1, 2011

Study Registration Dates

• First Submitted: July 7, 2009
• First Submitted That Met QC Criteria: July 17, 2009
• First Posted (Estimate): July 20, 2009

Study Record Updates

• Last Update Posted (Estimate): June 9, 2011
• Last Update Submitted That Met QC Criteria: June 7, 2011
• Last Verified: June 1, 2011

More Information

Terms related to this study

• Keywords: Mammography
• Other Study ID Numbers: TK01007